Advanced in Li-Fraumeni Syndrome

Dr. Jennifer K. Litton

Internal Medicine
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
Advanced in Li-Fraumeni Syndrome
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jennifer Litton is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Litton is rated as an Advanced provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, Canker Sore, and Aphthous Stomatitis.

Her clinical research consists of co-authoring 166 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Li-Fraumeni Syndrome.

Specialties
Internal Medicine
Licenses
Internal Medicine in TX
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

MD Anderson
2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Radiation, Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer
Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a PDL-1 Inhibitor in Patients With Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: Atezolizumab, Nab-paclitaxel
Study Phase: Phase 2
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
A Pilot Single Arm Open Label Trial Evaluating M7824 (Anti-PD-L1/TGF-Beta TRAP) in a Window Setting in Patients With Stage II-III HER2/Neu Positive (HER2+) Breast Cancer (BC)
Enrollment Status: Completed
Publish Date: October 22, 2024
Intervention Type: Drug
Study Drug: Bintrafusp Alfa
Study Phase: Phase 1
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Completed
Publish Date: June 05, 2024
Intervention Type: Biological
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Early Phase 1
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
A Phase Ib Trial of M7824 and Eribulin in Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Enrollment Status: Terminated
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Eribulin Mesylate
Study Phase: Phase 1
A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation
A Pilot Study of Talazoparib as a Neoadjuvant Study in Patients With a Diagnosis of Invasive Breast Cancer and a Deleterious BRCA Mutation
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Other, Drug
Study Drug: Talazoparib
Study Phase: Phase 2
RACHEL1: A Phase I Radiation and Checkpoint Blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
RACHEL1: A Phase I Radiation and Checkpoint Blockade Trial in Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Enrollment Status: Completed
Publish Date: March 07, 2022
Intervention Type: Drug, Radiation
Study Drug: Bintrafusp Alfa
Study Phase: Phase 1
View 6 Less Clinical Trials

166 Total Publications

ASO Visual Abstract: Complication Rates Are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy.
ASO Visual Abstract: Complication Rates Are Low After Invasive Procedures on the Lactating Breast in Patients Treated for Breast Cancer During Pregnancy.
Journal: Annals of surgical oncology
Published: August 07, 2025
Similar Doctors
Experienced in Li-Fraumeni Syndrome
Dr. Stacy L. Moulder
Internal Medicine
Experienced in Li-Fraumeni Syndrome
Dr. Stacy L. Moulder
Internal Medicine
1515 Holcombe Blvd, 
Houston, TX 
 (0.6 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances

Stacy Moulder is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Moulder is rated as a Distinguished provider by MediFind in the treatment of Li-Fraumeni Syndrome. Her top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, HER-2 Positive Breast Cancer, and Cerebral Hypoxia.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Litton's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile